Current Report Filing (8-k)
October 25 2019 - 4:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 21, 2019
Medicine
Man Technologies, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-36868
|
|
46-5289499
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
4880 Havana Street, Suite 201
Denver, Colorado
|
|
80239
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(303) 371-0387
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of
Incorporation or Bylaws; Change in Fiscal Year.
On October 21, 2019, the Board of Directors
of Medicine Man Technologies, Inc. (the “Company”) approved an amendment to its Bylaws, as amended. The amendment provides
for the Company’s directors to be divided into two classes, each serving for a period of two years. The Company’s directors
were previously divided into three classes, each serving for a period of either one, two or three years. A copy of the amendment
is attached as Exhibit 3.1 hereto.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
Medicine Man Technologies,
Inc.
|
|
|
Date: October 25, 2019
|
By: /s/ Andrew Williams
|
|
|
Andrew Williams
|
|
|
Chief Executive Officer
|
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Sep 2023 to Sep 2024